Expands eligible grantees under New Jersey Civic Information Consortium; establishes provisions for tracking and reporting progress of grantee; requires grantee to post statement on Internet website.
Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.